Home Cart Sign in  
Chemical Structure| 91374-20-8 Chemical Structure| 91374-20-8

Structure of Ropinirole HCl
CAS No.: 91374-20-8

Chemical Structure| 91374-20-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Ropinirole HCl selectively inhibit dopamine D2 receptor with Ki of 29 nM. It is used for the treatment of spontaneous parkinson's disease.

Synonyms: SKF 101468 hydrochloride; Ropinirole (hydrochloride); SKF-101468A

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Ropinirole HCl

CAS No. :91374-20-8
Formula : C16H25ClN2O
M.W : 296.84
SMILES Code : O=C1NC2=C(C(CCN(CCC)CCC)=CC=C2)C1.Cl
Synonyms :
SKF 101468 hydrochloride; Ropinirole (hydrochloride); SKF-101468A
MDL No. :MFCD01754173
InChI Key :XDXHAEQXIBQUEZ-UHFFFAOYSA-N
Pubchem ID :68727

Safety of Ropinirole HCl

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302-H319-H332-H372-H400
Precautionary Statements:P260-P264-P270-P273-P280-P301+P312+P330-P304+P312-P305+P351+P338-P314-P337+P313-P391-P501
Class:9
UN#:3077
Packing Group:

Related Pathways of Ropinirole HCl

GPCR

Isoform Comparison

Biological Activity

Target
  • D2 receptor

    D2 receptor, Ki:29 nM

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02339064 Idiopathic Parkinson's Disease Phase 3 Active, not recruiting October 2019 United States, Arizona ... More >> Phoenix, Arizona, United States, 85013 United States, California Loma Linda, California, United States, 92354 Los Angeles, California, United States, 90033 Los Angeles, California, United States, 90095 United States, Colorado Aurora, Colorado, United States, 80045 Englewood, Colorado, United States, 80113 United States, Florida Boca Raton, Florida, United States, 33486 United States, Georgia Atlanta, Georgia, United States, 30329 Augusta, Georgia, United States, 30912 United States, Illinois Chicago, Illinois, United States, 60611 Chicago, Illinois, United States, 60612 United States, Kansas Kansas City, Kansas, United States, 66160 United States, Michigan West Bloomfield, Michigan, United States, 48322 United States, New York Albany, New York, United States, 12208 United States, Ohio Cincinnati, Ohio, United States, 45219 United States, Oregon Portland, Oregon, United States, 97239 United States, Pennsylvania Philadelphia, Pennsylvania, United States, 19107 United States, Washington Kirkland, Washington, United States, 98034 Less <<
NCT02386423 Restless Leg Syndrome Not Applicable Completed - United States, Pennsylvania ... More >> Baycity Associated in Podiatry Inc Erie, Pennsylvania, United States, 16509 Less <<
NCT01052831 Impulse Control Disorder ... More >> Parkinson Disease Less << Phase 4 Completed - United States, Pennsylvania ... More >> University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104 Less <<
NCT01052831 - Completed - -
NCT02138357 Restless Legs Syndrome Phase 4 Withdrawn(No funding) - United States, Massachusetts ... More >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Less <<
NCT00605683 Idiopathic Parkinson's Disease Phase 3 Completed - -
NCT02994719 - Recruiting October 2019 United States, Massachusetts ... More >> Clinical Research Center BIDMC Recruiting Boston, Massachusetts, United States, 02215 Less <<
NCT01976871 Restless Legs Syndrome ... More >> Ekbom Syndrome Willis-Ekbom Disease Less << Phase 4 Completed - United States, Massachusetts ... More >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Less <<
NCT00040209 Parkinson Disease Phase 2 Completed - United States, Maryland ... More >> National Institute of Neurological Disorders and Stroke (NINDS) Bethesda, Maryland, United States, 20892 Less <<
NCT00076674 Dyskinesias P... More >>arkinson Disease Less << Phase 2 Completed - United States, Maryland ... More >> National Institute of Neurological Disorders and Stroke (NINDS) Bethesda, Maryland, United States, 20892 Less <<
NCT00108667 Parkinson Disease Phase 2 Completed - United States, Maryland ... More >> National Institute of Neurological Disorders and Stroke (NINDS) Bethesda, Maryland, United States, 20892 Less <<
NCT01898390 Parkinson's Disease Phase 1 Active, not recruiting December 2019 -
NCT00977184 Parkinson Disease Phase 1 Phase 2 Completed - United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT01515774 Parkinson's Disease Phase 4 Unknown October 2012 Korea, Republic of ... More >> Seoul National University Hospital Recruiting Seoul, Korea, Republic of, 110-744 Contact: Beom S. Jeon, MD, PhD    82-2-2072-2876    brain@snu.ac.kr    Contact: Ji Y Yun, MD    82-2-2072-0359    dream-yoon@hanmail.net    Principal Investigator: Beom S. Jeon, MD, PhD          Sub-Investigator: Han-Joon Kim, MD          Sub-Investigator: Ji Y Yun, MD          Sub-Investigator: Young Eun Kim, MD Less <<
NCT00977184 - Completed - -
NCT00465452 Parkinson Disease Phase 3 Completed - United States, Ohio ... More >> Medical University of Ohio Toledo, Ohio, United States, 43614 Less <<
NCT00086294 Parkinson's Disease ... More >> Dyskinesias Less << Phase 2 Completed - United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT00282152 Parkinson's Disease Not Applicable Completed - -
NCT00234364 - Completed - Denmark ... More >> Skejby Hospital Aarhus, Aahus N, Denmark, 8200 Less <<
NCT00399477 Parkinson's Disease Phase 4 Completed - -
NCT00282152 - Completed - -
NCT01393457 Cocaine Dependence Phase 2 Completed - United States, Texas ... More >> Behavioral and Biomedical Sciences Building Houston, Texas, United States, 77045 Less <<
NCT00051961 - Completed - United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT00305331 Parkinson's Disease ... More >> Peripheral Edema Less << Phase 2 Terminated(lack of recruitment... More >>) Less << - Canada, Ontario ... More >> Movement Disorders Clinic, Toronto Western Hospital, 399, Bathurst St Toronto, Ontario, Canada, M5V 2T8 Less <<
NCT01393457 - Completed - -
NCT01007864 Idiopathic Parkinson's Disease Phase 3 Completed - Germany ... More >> Ulm, Baden-Württemberg, Germany, 89081 Wolfach, Baden-Württemberg, Germany, 77709 München, Bayern, Germany, 80804 Berlin-Steglitz, Berlin, Germany, 12163 Marburg, Hessen, Germany, 35043 Göttingen, Niedersachsen, Germany, 37075 Dresden, Sachsen, Germany, 01307 Leipzig, Sachsen, Germany, 04107 Gera, Thüringen, Germany, 07551 Stadtroda, Thüringen, Germany, 07646 Berlin, Germany, 12200 Berlin, Germany, 13353 Less <<
NCT00381472 Parkinson Disease Phase 3 Completed - -
NCT00036218 Parkinson Disease Phase 3 Completed - -
NCT01723904 Advanced Parkinson's Disease Phase 3 Completed - Australia, New South Wales ... More >> 402 Chatswood, New South Wales, Australia 401 Sydney, New South Wales, Australia Australia, Victoria 403 Melbourne, Victoria, Australia Korea, Republic of 104 Busan, Korea, Republic of 112 Busan, Korea, Republic of 109 Daegu, Korea, Republic of 111 Gyeonggi-Do, Korea, Republic of 101 Seoul, Korea, Republic of 102 Seoul, Korea, Republic of 103 Seoul, Korea, Republic of 105 Seoul, Korea, Republic of 107 Seoul, Korea, Republic of 108 Seoul, Korea, Republic of 110 Seoul, Korea, Republic of Malaysia 202 Kuala Terengganu, Malaysia 204 Kuching Sarawak, Malaysia 201 Pulau Pinang, Malaysia Singapore 501 Singapore, Singapore 502 Singapore, Singapore Taiwan 302 Taichung, Taiwan 303 Tainan, Taiwan 306 Taipei, Taiwan Less <<
NCT01976871 - Completed - -
NCT00243971 Parkinson's Disease Phase 3 Completed - Germany ... More >> Schwarz Monheim, Germany Less <<
NCT00242008 Parkinson's Disease Phase 3 Completed - United States, North Carolina ... More >> Schwarz RTP, North Carolina, United States Less <<
NCT00256893 Fibromyalgia Syndrome, Primary Phase 2 Completed - Belgium ... More >> GSK Investigational Site Bruxelles, Belgium, 1070 GSK Investigational Site Diepenbeek, Belgium, 3590 GSK Investigational Site Merksem, Belgium, 2170 Denmark GSK Investigational Site Frederiksberg, Denmark, 2000 Finland GSK Investigational Site Jyvaskyla, Finland, 40100 GSK Investigational Site Kuopio, Finland, 70100 GSK Investigational Site Mikkeli, Finland, 50100 France GSK Investigational Site Lomme, France, 59160 GSK Investigational Site Paris, France, 75006 GSK Investigational Site Paris, France, 75012 Germany GSK Investigational Site Fellbach, Baden-Wuerttemberg, Germany, 70736 GSK Investigational Site Heidelberg, Baden-Wuerttemberg, Germany, 69120 GSK Investigational Site Bad Hersfeld, Hessen, Germany, 36251 GSK Investigational Site Huettenberg, Hessen, Germany, 35625 Italy GSK Investigational Site Benevento, Campania, Italy, 82100 GSK Investigational Site Roma, Lazio, Italy, 00161 GSK Investigational Site Milano, Lombardia, Italy, 20157 Netherlands GSK Investigational Site Zwolle, Netherlands, 8011 JW Sweden GSK Investigational Site Mölndal, Sweden, SE-431 37 United Kingdom GSK Investigational Site Cambridge, Cambridgeshire, United Kingdom, CB2 0QQ GSK Investigational Site Truro, Cornwall, United Kingdom, TR1 3LJ GSK Investigational Site Poole, Dorset, United Kingdom, BH15 2JB Less <<
NCT00344994 Restless Legs Syndrome Phase 4 Completed - United States, Georgia ... More >> Medical College of Georgia Augusta, Georgia, United States, 30912 Less <<
NCT00367822 Restless Legs Syndrome Phase 3 Completed - Germany ... More >> IMEREM GmbH Nuremberg, Germany Less <<
NCT01723904 - Completed - -
NCT00593606 Parkinson's Disease Phase 3 Completed - -
NCT01711866 - Completed - -
NCT00363727 Parkinson's Disease ... More >> Parkinson Disease Dyskinesias Less << Phase 3 Completed - -
NCT01711866 Advanced Idiopathic Parkinson'... More >>s Disease Less << Phase 4 Completed - United States, Alabama ... More >> 505 Anniston, Alabama, United States United States, Florida 506 Atlantis, Florida, United States 508 Miami Springs, Florida, United States United States, Georgia 502 Atlanta, Georgia, United States United States, Ohio 501 Dayton, Ohio, United States United States, Oklahoma 509 Oklahoma City, Oklahoma, United States Korea, Republic of 101 Busan, Korea, Republic of 102 Busan, Korea, Republic of 108 Daegu, Korea, Republic of 109 Daegu, Korea, Republic of 105 Gyeonggi-Do, Korea, Republic of 103 Seoul, Korea, Republic of 104 Seoul, Korea, Republic of 106 Seoul, Korea, Republic of 107 Seoul, Korea, Republic of Malaysia 202 Sarawak, Malaysia Singapore 401 Singapore, Singapore 403 Singapore, Singapore Taiwan 301 Linkou, Taiwan 304 Taichung, Taiwan 305 Taipei, Taiwan Less <<
NCT00285727 Depressive Disorder, Major Not Applicable Completed - United States, California ... More >> Stanford University School of Medicine Stanford, California, United States, 94305 Depression Research Clinic, Psychiatry Department, Stanford School of Medicine Stanford, California, United States, 9430 Less <<
NCT00197080 Restless Legs Syndrome Phase 3 Completed - -
NCT00829504 Healthy Phase 1 Completed - United States, Texas ... More >> Novum Pharmaceutical Research Services Houston, Texas, United States, 77042 Less <<
NCT00221390 Cerebrovascular Accident ... More >> Hemiparesis Less << Phase 2 Completed - United States, California ... More >> University of California, Irvine Medical Center Orange, California, United States, 92868 Less <<
NCT00593606 - Completed - -
NCT00422994 Restless Legs Syndrome Phase 1 Completed - United States, Minnesota ... More >> GSK Investigational Site Minneapolis, Minnesota, United States, 55404 United Kingdom GSK Investigational Site London, United Kingdom, SW17 0QT Less <<
NCT00829504 - Completed - -
NCT00225862 Restless Legs Syndrome Phase 3 Completed - -
NCT00335205 Bipolar Disorder ... More >> Major Depressive Disorder Less << Phase 4 Unknown - Israel ... More >> Jerusalem Mental Health Center Active, not recruiting Jerusalem, Israel Chaim Sheba Medical Center, Dept. of Psychiatry Recruiting Tel Hashomer, Israel, 52621 Contact: Ari A Gershon, MD    +972-3-5349105    agershon@sheba.health.gov.il Less <<
NCT00357097 - Completed - -
NCT00363857 Restless Legs Syndrome (RLS) ... More >> Restless Legs Syndrome Less << Phase 3 Completed - -
NCT00357097 Restless Legs Syndrome ... More >> Moderate to Severe Idiopathic Restless Legs Syndrome (RLS) Less << Phase 3 Completed - -
NCT00830219 - Completed - -
NCT00830219 Healthy Phase 1 Completed - United States, Texas ... More >> Novum Pharmaceutical Research Services Houston, Texas, United States, 77042 Less <<
NCT00144300 - Completed - -
NCT00996944 Restless Legs Syndrome Phase 2 Terminated(Because GSK conclud... More >>ed that it was impossible to recruit sufficient participants within a reasonable timeframe.) Less << - Japan ... More >> GSK Investigational Site Aichi, Japan, 440-0035 GSK Investigational Site Aichi, Japan, 453-8566 GSK Investigational Site Chiba, Japan, 277-0084 GSK Investigational Site Chiba, Japan, 289-2511 GSK Investigational Site Fukuoka, Japan, 803-0844 GSK Investigational Site Hiroshima, Japan, 737-0131 GSK Investigational Site Hokkaido, Japan, 070-0030 GSK Investigational Site Hyogo, Japan, 670-0947 GSK Investigational Site Ibaraki, Japan, 300-0053 GSK Investigational Site Ibaraki, Japan, 302-0022 GSK Investigational Site Kagawa, Japan, 761-8024 GSK Investigational Site Miyagi, Japan, 981-0911 GSK Investigational Site Nagano, Japan, 392-8510 GSK Investigational Site Nagasaki, Japan, 850-0052 GSK Investigational Site Okinawa, Japan, 901-2132 GSK Investigational Site Okinawa, Japan, 904-2143 GSK Investigational Site Osaka, Japan, 547-0024 GSK Investigational Site Shizuoka, Japan, 424-0012 GSK Investigational Site Tokushima, Japan, 770-0011 Less <<
NCT00673088 Parkinson's Disease ... More >> Restless Leg Syndrome Less << Not Applicable Completed - -
NCT00144300 Parkinson Disease Phase 4 Completed - -
NCT01494532 Parkinson Disease Phase 4 Completed - -
NCT00373542 Restless Legs Syndrome (RLS) ... More >> Restless Legs Syndrome Less << Phase 4 Completed - -
NCT00674310 Parkinson's Disease ... More >> Restless Leg Syndrome Less << Not Applicable Completed - -
NCT00334048 Sexual Dysfunction Phase 4 Completed - United States, New York ... More >> Mood Disorders Research Program New York, New York, United States, 10019 Less <<
NCT01494532 - Completed - -
NCT01628926 Parkinson's Disease Phase 3 Completed - Japan ... More >> Chubu Region, Japan Chugoku Region, Japan Hokkaido Region, Japan Kanto Region, Japan Kinki Region, Japan Kyushu Region, Japan Shikoku Region, Japan Tohoku Region, Japan Less <<
NCT01628926 - Completed - -
NCT00434304 Parkinson Disease Phase 2 Completed - Japan ... More >> GSK Investigational Site Aichi, Japan, 455-8530 GSK Investigational Site Aichi, Japan, 460-0008 GSK Investigational Site Chiba, Japan, 279-0021 GSK Investigational Site Ehime, Japan, 791-0295 GSK Investigational Site Hokkaido, Japan, 070-0901 GSK Investigational Site Iwate, Japan, 020-0878 GSK Investigational Site Kanagawa, Japan, 251-0038 GSK Investigational Site Kyoto, Japan, 600-8811 GSK Investigational Site Osaka, Japan, 570-8507 GSK Investigational Site Saitama, Japan, 343-0032 GSK Investigational Site Tokyo, Japan, 113-8431 GSK Investigational Site Tokyo, Japan, 136-0075 Less <<
NCT00996944 - Terminated(Because GSK conclud... More >>ed that it was impossible to recruit sufficient participants within a reasonable timeframe.) Less << - -
NCT00314860 Restless Legs Syndrome ... More >> Restless Legs Syndrome (RLS) Less << Phase 3 Completed - -
NCT00434304 - Completed - -
NCT00260793 Parkinson's Disease Phase 3 Unknown - United States, Colorado ... More >> Colorado Neurology, P.C. Recruiting Englewood, Colorado, United States, 80113 Contact: Deborah Judd, RN, CCRC    303-762-6667    judd@megapathdsl.net    Principal Investigator: Pinky Agarwal, MD Less <<
NCT00331149 Parkinson Disease Phase 3 Completed - -
NCT00256854 Restless Legs Syndrome ... More >> Restless Legs Syndrome (RLS) Less << Phase 3 Completed - -
NCT00275275 Parkinson Disease Phase 3 Completed - United States, Kansas ... More >> University of Kansas Medical Center Kansas City, Kansas, United States, 66160 Less <<
NCT00460148 Parkinson Disease Phase 2 Completed - Germany ... More >> GSK Investigational Site Berlin, Germany, 10117 South Africa GSK Investigational Site George, Eastern Cape, South Africa, 6529 Less <<
NCT01154166 Parkinson Disease Phase 3 Completed - China, Guangdong ... More >> GSK Investigational Site Guangzhou, Guangdong, China, 510120 China, Hubei GSK Investigational Site Wuhan, Hubei, China, 430022 China, Jiangsu GSK Investigational Site Suzhou, Jiangsu, China, 215004 China, Shaanxi GSK Investigational Site Xian, Shaanxi, China, 710061 China, Sichuan GSK Investigational Site Chengdu, Sichuan, China, 610041 GSK Investigational Site Chengdu, Sichuan, China, 610072 China, Yunnan GSK Investigational Site Kunming, Yunnan, China, 650032 GSK Investigational Site Kunming, Yunnan, China, 650101 China, Zhejiang GSK Investigational Site Hangzhou, Zhejiang, China, 310009 China GSK Investigational Site Beijing, China, 100034 GSK Investigational Site Beijing, China, 100050 GSK Investigational Site Beijing, China, 100053 GSK Investigational Site Beijing, China, 100730 GSK Investigational Site Beijing, China, 100853 GSK Investigational Site Shanghai, China, 200025 GSK Investigational Site Shanghai, China, 200032 GSK Investigational Site Shanghai, China, 200040 GSK Investigational Site Tianjin, China, 300052 Less <<
NCT00275275 - Completed - -
NCT03038308 Hyperprolactinemia ... More >> Prolactinoma Less << Phase 1 Phase 2 Recruiting July 1, 2019 United States, New York ... More >> Columbia University Medical Center Recruiting New York, New York, United States, 10032 Contact: Gabrielle Page-Wilson, M.D.    212-305-3725    gp2287@cumc.columbia.edu Less <<
NCT00650104 Parkinson Disease Phase 3 Completed - United States, Arizona ... More >> GSK Investigational Site Scottsdale, Arizona, United States, 85259 United States, California GSK Investigational Site Los Angeles, California, United States, 90033 GSK Investigational Site Oxnard, California, United States, 93030 United States, Florida GSK Investigational Site Miami, Florida, United States, 33136 GSK Investigational Site Tampa, Florida, United States, 33606 United States, Georgia GSK Investigational Site Augusta, Georgia, United States, 30912 United States, Kansas GSK Investigational Site Kansas City, Kansas, United States, 66160 United States, New Jersey GSK Investigational Site Edison, New Jersey, United States, 08818 United States, Pennsylvania GSK Investigational Site Upland, Pennsylvania, United States, 19013 United States, Texas GSK Investigational Site Houston, Texas, United States, 77030 Less <<
NCT00639119 Unverricht-Lundborg Syndrome Phase 2 Unknown - Finland ... More >> Turku university central hospital, Department of neurology Turku, Finland, 20520 Less <<
NCT00650104 - Completed - -
NCT01154166 - Completed - -
NCT00355641 Restless Legs Syndrome Phase 3 Completed - -
NCT01485172 Parkinson Disease Phase 4 Completed - -
NCT00314821 Bipolar Disorder Phase 4 Completed - United States, Georgia ... More >> Emory University Atlanta, Georgia, United States, 30322 United States, Massachusetts Cambridge Health Alliance Cambridge, Massachusetts, United States, 02139 Less <<
NCT01371682 Parkinson Disease Phase 1 Completed - Belgium ... More >> GSK Investigational Site Antwerpen, Belgium, 2060 Less <<
NCT00530790 Restless Legs Syndrome Phase 2 Completed - Japan ... More >> GSK Investigational Site Fukuoka, Japan, 802-0084 GSK Investigational Site Fukuoka, Japan, 810-0044 GSK Investigational Site Fukuoka, Japan, 830-0011 GSK Investigational Site Hiroshima, Japan, 733-0031 GSK Investigational Site Kanagawa, Japan, 210-0024 GSK Investigational Site Osaka, Japan, 550-0004 GSK Investigational Site Osaka, Japan, 589-0022 GSK Investigational Site Osaka, Japan, 599-8263 GSK Investigational Site Tochigi, Japan, 321-0293 GSK Investigational Site Tokyo, Japan, 151-0053 GSK Investigational Site Tokyo, Japan, 187-0041 Less <<
NCT01485172 - Completed - -
NCT00329602 - Completed - -
NCT00632736 Parkinson Disease ... More >> Parkinson's Disease Less << Phase 3 Completed - -
NCT00419692 Restless Legs Syndrome Phase 1 Completed - Germany ... More >> GSK Investigational Site Berlin, Germany, 14050 South Africa GSK Investigational Site George, South Africa, 6530 Less <<
NCT00632736 - Completed - -
NCT00530790 - Completed - -
NCT00329602 Restless Legs Syndrome Phase 4 Completed - -
NCT00140712 Restless Legs Syndrome Phase 1 Completed - United States, District of Col... More >>umbia GSK Investigational Site Washington, D.C., District of Columbia, United States, 20010 United States, Georgia GSK Investigational Site Macon, Georgia, United States, 31201 United States, Illinois GSK Investigational Site Chicago, Illinois, United States, 60611 United States, Kentucky GSK Investigational Site Louisville, Kentucky, United States, 40202 United States, Missouri GSK Investigational Site Kansas City, Missouri, United States, 64108 United States, New Jersey GSK Investigational Site Edison, New Jersey, United States, 08818 United States, North Carolina GSK Investigational Site Chapel Hill, North Carolina, United States, 27599 Belgium GSK Investigational Site Bruxelles, Belgium, 1020 France GSK Investigational Site Paris, France, 75019 Less <<
NCT01536574 Parkinson Disease Phase 3 Completed - China, Guangdong ... More >> GSK Investigational Site Guangzhou, Guangdong, China, 510120 China, Hubei GSK Investigational Site Wuhan, Hubei, China, 430022 China, Jiangsu GSK Investigational Site Suzhou, Jiangsu, China, 215004 China, Shaanxi GSK Investigational Site Xian, Shaanxi, China, 710061 China, Sichuan GSK Investigational Site Chengdu, Sichuan, China, 610041 GSK Investigational Site Chengdu, Sichuan, China, 610072 China, Yunnan GSK Investigational Site Kunming, Yunnan, China, 650032 GSK Investigational Site Kunming, Yunnan, China, 650101 China, Zhejiang GSK Investigational Site Hangzhou, Zhejiang, China, 310009 China GSK Investigational Site Beijing, China, 100034 GSK Investigational Site Beijing, China, 100050 GSK Investigational Site Beijing, China, 100053 GSK Investigational Site Beijing, China, 100730 GSK Investigational Site Beijing, China, 100853 GSK Investigational Site Shanghai, China, 200025 GSK Investigational Site Shanghai, China, 200032 GSK Investigational Site Shanghai, China, 200040 GSK Investigational Site Tianjin, China, 300052 Less <<
NCT01536574 - Completed - -
NCT01435915 Parkinson Disease Phase 1 Completed - China ... More >> GSK Investigational Site Beijing, China, 100032 Less <<
NCT00485069 - Completed - -
NCT00485069 Parkinson Disease ... More >> Parkinson's Disease Less << Phase 4 Completed - Japan ... More >> GSK Investigational Site Chiba, Japan, 270-2251 GSK Investigational Site Fukuoka, Japan, 814-0180 GSK Investigational Site Fukuoka, Japan, 816-0943 GSK Investigational Site Fukuoka, Japan, 819-8585 GSK Investigational Site Hyogo, Japan, 651-2273 GSK Investigational Site Ibaraki, Japan, 300-0053 GSK Investigational Site Iwate, Japan, 020-8505 GSK Investigational Site Kanagawa, Japan, 247-8533 GSK Investigational Site Kanagawa, Japan, 253-8558 GSK Investigational Site Kyoto, Japan, 616-8255 GSK Investigational Site Miyagi, Japan, 982-8555 GSK Investigational Site Miyagi, Japan, 989-2202 GSK Investigational Site Osaka, Japan, 543-8555 GSK Investigational Site Osaka, Japan, 558-8558 GSK Investigational Site Osaka, Japan, 578-8588 GSK Investigational Site Osaka, Japan, 590-0132 GSK Investigational Site Osaka, Japan, 598-0048 GSK Investigational Site Saga, Japan, 849-8501 GSK Investigational Site Saitama, Japan, 364-8501 GSK Investigational Site Tokyo, Japan, 154-8551 GSK Investigational Site Tokyo, Japan, 160-0017 GSK Investigational Site Tokyo, Japan, 187-8551 Less <<
NCT01929317 Parkinson Disease Phase 3 Terminated - Japan ... More >> GSK Investigational Site Aichi, Japan, 466-8560 GSK Investigational Site Akita, Japan, 010-0874 GSK Investigational Site Aomori, Japan, 030-8553 GSK Investigational Site Hokkaido, Japan, 070-8530 GSK Investigational Site Hokkaido, Japan, 070-8644 GSK Investigational Site Hyogo, Japan, 672-8043 GSK Investigational Site Hyogo, Japan, 674-0081 GSK Investigational Site Iwate, Japan, 020-0878 GSK Investigational Site Iwate, Japan, 025-0075 GSK Investigational Site Kagawa, Japan, 760-0027 GSK Investigational Site Kanagawa, Japan, 252-0392 GSK Investigational Site Kyoto, Japan, 600-8811 GSK Investigational Site Okayama, Japan, 703-8265 GSK Investigational Site Osaka, Japan, 530-8480 GSK Investigational Site Osaka, Japan, 578-8588 GSK Investigational Site Shizuoka, Japan, 416-0955 GSK Investigational Site Shizuoka, Japan, 433-8125 Less <<
NCT00823836 Parkinson Disease Phase 3 Completed - -
NCT01327339 - Completed - -
NCT01327339 - Completed - -
NCT01929317 - Terminated - -
NCT03176966 Muscle Cramp ... More >>Cirrhosis Less << Phase 4 Enrolling by invitation July 2020 United States, Tennessee ... More >> Vanderbilt University Medical Center Nashville, Tennessee, United States, 37212 Less <<
NCT00986245 - Completed - -
NCT01627847 Healthy Phase 1 Completed - India ... More >> GVK Biosciences Pvt. Ltd Ameerpet, Hyderabad, Andhra Pradesh, India, 500 038 Less <<
NCT03708237 Restless Legs Syndrome ... More >> End Stage Renal Disease Less << Phase 2 Not yet recruiting November 30, 2019 -
NCT01627834 Healthy Phase 1 Completed - India ... More >> GVK Biosciences Pvt. Ltd Ameerpet, Hyderabad, India, 500 038 Less <<
NCT01712568 Pharmacokinetic Study Phase 1 Completed - India ... More >> Sipra Labs Limited Hyderabad, Andhra Pradesh, India, 500 038 Less <<
NCT00823836 - Completed - -
NCT01714856 Pharmacokinetic Study Phase 1 Completed - India ... More >> Sipra Labs Limited Hyderabad, Andhra Pradesh, India, 500 038 Less <<
NCT01717235 Pharmacokinetic Study Phase 1 Completed - India ... More >> Sipra Labs Limited Hyderabad,, Andhra Pradesh,, India, 500 038 Less <<
NCT03250117 Parkinson Disease Phase 1 Phase 2 Recruiting December 2018 United States, Florida ... More >> Orlando, Florida Recruiting Orlando, Florida, United States, 32806 Contact    407-210-1157       United States, Michigan Farmington Hills, Michigan Recruiting Farmington Hills, Michigan, United States, 48334 Contact    248-957-8940       United States, Washington Kirkland, Washington Recruiting Kirkland, Washington, United States, 98034 Contact    425-899-5385 Less <<
NCT00986245 Parkinson Disease Phase 4 Completed - Korea, Republic of ... More >> Seoul National University Hospital Seoul, Korea, Republic of, 110-744 Boramae City Hospital Seoul, Korea, Republic of Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.37mL

0.67mL

0.34mL

16.84mL

3.37mL

1.68mL

33.69mL

6.74mL

3.37mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories